Acute liver failure

Reading File

Finding Sources

Searching PubMed

"acute liver failure"[MeSH Terms]

Searching Images

acute liver failure pathophysiology management

This medical infographic illustrates the pathophysiology of macrophage activation in Acute-on-Chronic Liver Failure (ACLF). The diagram depicts hepatic (e.g., alcohol, HBV/HCV, DILI) and extra-hepatic (e.g., bacterial infections, surgery) precipitating factors that trigger the release of PAMPs and DAMPs. These molecules activate liver resident macrophages, or Kupffer cells. Within the liver, the diagram shows upregulated expression and increased shedding of membrane-bound CD163 and CD206 from Kupffer cells. The shedding of CD163 occurs via TACE-cleavage and extracellular vesicle (EV) release, while CD206 is shed via proteolytic cleavage and EV-release. Two bar graphs demonstrate the clinical significance of these processes, showing a stepwise increase in plasma concentrations of soluble CD163 (sCD163) and soluble CD206 (sCD206) correlating with ACLF severity (Healthy Control vs. Grades 1-3). The infographic identifies sCD163 and sCD206 as prognostic biomarkers for disease severity and mortality in patients with acute decompensation (AD) and ACLF, highlighting their role in monitoring hepatology patients.

A pathophysiology diagram illustrating the liver acute phase response in the context of cancer and potential points of therapeutic intervention. The process begins with 'Inflammatory Factors' (IL-6, IL-1̧́, and microbial products) triggering a 'Liver Acute Phase Response.' This response results in the production and secretion of 'Acute phase proteins' by the liver. These proteins drive systemic 'Pathology,' categorized into four clinical outcomes: inflammation, immune dysfunction, altered metabolism, and fibrosis. The diagram outlines three numbered strategies for medical intervention: (1) blocking the primary triggers of liver inflammation (e.g., anti-IL-6 antibodies), (2) restoring liver homeostasis by modulating the hepatic cellular response (e.g., STAT3 inhibition), and (3) intervening on acute phase protein signaling by neutralizing the proteins themselves or their downstream receptors (e.g., TLR inhibitors). The illustration emphasizes the liver's role as a central sensor in cancer-associated systemic inflammation and its potential as a target for treating complications like cachexia and metastasis.

This composite educational graphic illustrates the use of poly(oxalate-co-curcumin) (POC) particles as theranostic agents for acetaminophen (APAP)-induced acute liver failure (ALF) in a murine model. Panel (a) contains a pathophysiology diagram showing the synthesis of POC particles and their mechanism: in the presence of hydrogen peroxide (H2O2) within the injured liver, POC particles undergo an H2O2-responsive degradation to release curcumin (anti-inflammatory) and generate CO2 bubbles (ultrasound contrast). Panel (b) is a bar chart comparing serum alanine aminotransferase (ALT) levels across groups, demonstrating that POC particles significantly reduce hepatic enzymes compared to APAP-only or free curcumin (CUR) treatments. Panel (c) presents longitudinal diagnostic ultrasound images of mouse livers. The liver contours are outlined in red. In the APAP + POC group, there is a progressive increase in echogenicity (bright signals indicated by yellow arrows) from 5 to 60 minutes post-treatment, representing real-time monitoring of ROS-triggered CO2 bubble generation, while control and APAP-only groups remain hypoechoic.

Reading File

I now have comprehensive information from multiple authoritative surgical textbooks. Let me compile the full, detailed response.

Acute Liver Failure (ALF)

Definition

ALF is a clinical syndrome of severe hepatic injury characterized by the triad of:

Elevated transaminases (hepatocellular injury)
Coagulopathy (PT prolonged / INR > 1.5)
Hepatic encephalopathy (HE)

...occurring in a patient without pre-existing liver disease, within 26 weeks of the onset of symptoms. Encephalopathy is an essential component - its presence is required for the diagnosis and for listing in the most urgent transplant category (UNOS Status 1A).

Sabiston Textbook of Surgery, p. 1068
Current Surgical Therapy 14e, p. 460

Classification by Time Course

Subtype	Onset of encephalopathy after symptoms
Hyperacute	Within 7 days
Acute	7 - 21 days
Subacute (Subfulminant)	21 days - 26 weeks

The shorter the symptom duration, the more likely the patient is to develop cerebral edema. Patients with a longer course more commonly present with portal hypertension.

Epidemiology

Affects approximately 2,000-3,000 Americans per year
73% of patients are female, median age 38 years
84% are referred from outside hospitals
~44% acquire a culture-proven infection during admission
Before liver transplantation, survival was < 20%; current 5-year survival > 70%
Schwartz's Principles of Surgery, p. 1388

Etiology

Geographic Variation

Western countries (USA, UK, Australia): Drug-induced liver injury (DILI) predominates - 65% of cases
Eastern/developing world: Viral hepatitis (B, A, E) predominates

Common Causes in the USA (US Acute Liver Failure Study Group - 308 patients)

Cause	Prevalence
Acetaminophen overdose	~40%
Idiosyncratic drug-induced liver injury	13%
Indeterminate	17%
Hepatitis B	6%
Ischemic hepatitis	6%
Autoimmune hepatitis	4%
Hepatitis A	4%
Wilson's disease	3%
Pregnancy-related	2%
Budd-Chiari syndrome	2%
Malignancy	1%

Risk factors for acetaminophen-induced ALF: Concurrent alcohol use, malnutrition, or drugs that induce CYP450 enzymes (phenytoin, carbamazepine, rifampin).

Current Surgical Therapy 14e, p. 459

Pathophysiology and Complications

1. Hepatic Encephalopathy & Cerebral Edema

Hyperammonemia is the critical driver
Cerebral edema develops in ~80% of patients reaching grade 4 HE
Ammonia levels > 200 µmol/L are associated with increased risk of cerebral edema and intracranial hypertension
ALF-induced encephalopathy is different from cirrhotic encephalopathy - cerebral edema does not develop in chronic liver disease, so lactulose has not been shown to improve survival in ALF
Raised ICP → decreased cerebral perfusion pressure → ischemic brain damage and herniation
Most common cause of death is cerebral edema/intracranial hypertension, accounting for > half of ALF-associated mortality

2. Coagulopathy

Impaired synthesis of clotting factors
INR/PT prolongation; FFP and platelets reserved for active bleeding or pre-procedure

3. Renal Failure

Occurs in ~40% (creatinine > 2.0 mg/dL in 40% at admission)
Requires continuous venovenous hemodialysis (CVVHD) rather than intermittent hemodialysis - provides better hemodynamic and ICP stability
CRRT also effective for rapid ammonia clearance

4. Infection / Sepsis

High susceptibility to bacterial and fungal infections
Surveillance cultures should be performed early

5. Metabolic Disturbances

Hypophosphatemia - a sign of hepatic regeneration; may indicate higher likelihood of spontaneous recovery; correct with IV phosphate
Hypoglycemia (impaired gluconeogenesis)
Acid-base disturbances (pH < 7.30 at presentation in 14%)

6. Hemodynamic Instability

Hyperdynamic circulation; vasopressor support often needed
Current Surgical Therapy 14e, p. 460; Schwartz's, p. 1388-1389

Clinical Presentation

Jaundice, malaise, nausea/vomiting
Progressive encephalopathy (grades I-IV)
Signs of coagulopathy (easy bruising, bleeding)
Rapid deterioration possible over hours-days
Median: 6 days ill before onset of encephalopathy; 2 days from jaundice to encephalopathy

Laboratory Evaluation

Category	Tests
Baseline	CBC, comprehensive metabolic panel, amylase/lipase, LFTs
Coagulation	PT/INR, Factor V level, Factor VII level
Blood gas	Arterial blood gas, arterial ammonia
Typing	ABO
Etiology screen	Acute hepatitis panel (HAV IgM, HBsAg, HCV), autoimmune markers, ceruloplasmin, toxicology screen, acetaminophen level, HIV, pregnancy test

Schwartz's Principles of Surgery, p. 1388

Management

General Measures

Immediate transfer to a liver transplant center - disease can progress rapidly
ICU admission for close monitoring
Head of bed elevated ≥ 30 degrees
Avoid sedation (impairs neurological assessment); sedation/paralysis only when needed to minimize stimulation
Avoid nephrotoxic medications
Euglycemia maintenance
Maintain serum sodium 140-145 mmol/L (hypertonic saline as needed)
Liver biopsy (transjugular approach due to coagulopathy) if autoimmune hepatitis or lymphoma is suspected

Specific Therapies

Condition	Treatment
Acetaminophen overdose	Activated charcoal (if within a few hours of ingestion) + N-acetylcysteine (NAC)
NAC dosing (oral)	140 mg/kg loading dose, then 70 mg/kg q4h × 17 doses
NAC dosing (IV)	150 mg/kg loading, then 50 mg/kg q4h × 12 doses
ALF of unclear etiology	NAC still recommended (glutathione replenishment)
Drug-induced ALF	Discontinue all suspected offending agents
Hepatitis B	Antiviral therapy
Autoimmune hepatitis	Corticosteroids
Wilson's disease	Chelation; transplant often required

Cerebral Edema / Raised ICP Management

Head of bed 30 degrees
Minimize stimulation (sedation/paralysis if needed)
Hypertonic saline (200 mL of 2.7%, or 20 mL of 30%) for clinical signs of raised ICP
IV mannitol (150 mL, 20%) over 20 minutes
Hyperventilation to PaCO2 25-30 mmHg (acute cerebral vasoconstriction)
ICP monitoring (bolt): controversial due to bleeding risk; if used, target ICP < 20-25 mmHg, CPP > 50 mmHg
Head CT: insensitive early, but useful to rule out hemorrhage; use with caution as moving severely encephalopathic patients can cause ICP surges
Noninvasive alternatives: transcranial Doppler, jugular venous oximetry

Extracorporeal Liver Support Devices

System	Mechanism	Evidence
MARS (Molecular Adsorbent Recirculating System)	Albumin dialysis - removes protein-bound and water-soluble toxins	Improves HE symptoms; no clear mortality benefit in RCTs
Prometheus system	Fractionated plasma separation + adsorption + dialysis	Safety shown; no mortality benefit in ACLF
SPAD (Single-pass albumin dialysis)	Albumin-impermeable high-flux membrane	No impact on survival in available studies
High-volume plasma exchange (HVP)	Removes toxins + replaces coagulation factors	Small studies suggest survival benefit; further research needed

Current Surgical Therapy 14e, p. 493

Prognostic Scoring - King's College Criteria

Used to identify patients who are unlikely to survive without liver transplantation.

Acetaminophen-related ALF

Arterial pH < 7.3 (after resuscitation)
OR
INR > 6.5 AND serum creatinine > 3.4 mg/dL
AND Grade III or IV encephalopathy

Non-Acetaminophen ALF

INR > 6.5
OR any 3 of the following:
- INR > 3.5
- Bilirubin > 17.6 mg/dL
- Age < 10 or > 40 years
- Cause: drug toxicity or indeterminate
- Time from onset of jaundice to encephalopathy > 7 days

Positive predictive value: 80-100%

Other scoring: MELD score is also used; evidence suggests King's College criteria may be more accurate specifically for acetaminophen-associated ALF.

Current Surgical Therapy 14e, p. 461; Sabiston, p. 1068

Liver Transplantation

Only definitive treatment for patients who meet criteria and fail to improve
Successful transplantation: 84% 1-year survival (USA data); 73% 5-year survival (single-center data); registry data shows 80% 1-year graft survival
Superior to no transplant in the right patient, but inferior to spontaneous recovery
Contraindicated if CT shows evidence of irreversible brain injury or uncal herniation
Key challenge: Expeditiously identifying who needs transplant vs. who will recover (particularly difficult in young acetaminophen overdose patients with social/psychiatric comorbidities)
Progression to stage II encephalopathy is often used as a trigger to move toward transplant evaluation

Status 1A listing: Reserved for patients with ALF who have encephalopathy.

Summary of Key Points

Feature	Detail
Definition	Encephalopathy + coagulopathy + no prior liver disease, within 26 weeks
#1 cause (West)	Acetaminophen overdose (~40% USA)
#1 cause (East)	Viral hepatitis (B, A, E)
Most common death	Cerebral edema / intracranial hypertension
Key antidote	N-acetylcysteine (NAC) for acetaminophen
Prognostic tool	King's College Criteria
Definitive Rx	Liver transplantation (Status 1A)
Lactulose in ALF	Not effective (unlike cirrhosis)
CRRT advantage	Better ICP + hemodynamic stability vs. IHD
Hypophosphatemia	Sign of hepatic regeneration - favorable prognostic sign

Can eating Chinese food cause it

Finding Sources

Searching the Web

Chinese food herbal medicine acute liver failure cause

Short answer: No, eating ordinary Chinese food (a restaurant meal) will not cause acute liver failure. However, the question touches on something genuinely important in hepatology - Chinese herbal medicines (CHM) are a well-documented cause of drug-induced liver injury (DILI) and can, in severe cases, progress to ALF.

Here is the full picture:

Ordinary Chinese Food and ALF

No. Standard Chinese cuisine - rice, noodles, vegetables, meat, soy sauce, tofu, etc. - does not cause acute liver failure. Normal food, regardless of cuisine, is not a recognized cause of ALF.

The only very remote food-related exceptions would be:

Amanita phalloides (death cap mushroom) toxin - sometimes used in wild mushroom foraging; misidentification of medicinal mushrooms has led to liver failure, as noted in Harrison's Principles of Internal Medicine 22E. This is not a "Chinese food" issue per se, but is relevant in East Asian contexts where wild mushroom foraging is culturally common.

Chinese Herbal Medicine (CHM) - A Real and Significant Risk

This is where the concern is legitimate. CHM is the most relevant "Chinese" link to ALF.

Of 9,355 total DILI cases reported in Chinese academic journals from 2001-2010, approximately 20% were associated with herbs
Another study found 44.2% of all DILI cases were caused by CHM
CHM-induced liver injury accounts for 26-49% of DILI in Chinese literature from 2013
A 2014 study (PMID 24335449) found that 30% of ALF patients had accepted herbal therapies before onset; 60% of those patients died

Specific Chinese Herbal Products Linked to Liver Injury / ALF

These are documented by NIH LiverTox:

Herb / Product	Notes
Jin Bu Huan	Sedative/analgesic; causes hepatitis and acute liver failure
Ma Huang (Ephedra)	Stimulant; weight-loss products; hepatotoxic
Shou Wu Pian (He Shou Wu / Fo-Ti)	Used for hair/anti-aging; well-documented hepatotoxicity
Ba Jiao Lian	Used in TCM; contains podophyllotoxin; hepatotoxic
Chi R Yun	Reported liver injury cases
Aristolochia species	Associated with severe nephropathy and hepatotoxicity

Of the 7,000+ Chinese herbal medications in existence, only a small number have been directly linked to clinically apparent liver injury.

Why Does This Happen?

Direct hepatotoxicity - Some plant alkaloids and compounds are directly toxic to hepatocytes
Idiosyncratic reactions - Unpredictable immune-mediated responses, dose-independent
Adulteration - Some herbal products contain heavy metals (arsenic, lead, mercury) or undisclosed pharmaceutical drugs
Misidentification - One plant species substituted for another with different toxicity
Synergistic toxicity - Combination of multiple herbs with overlapping hepatotoxic profiles

Bottom Line

Scenario	Risk of ALF
Eating Chinese restaurant food	None
Taking Chinese herbal medicine (TCM) products	Real risk - especially He Shou Wu, Jin Bu Huan, Ma Huang
Wild mushroom consumption with misidentification	Rare but severe risk

If someone develops jaundice, fatigue, or abdominal pain after taking any TCM herbal supplements, the suspect product should be stopped immediately and a doctor consulted without delay. As the LiverTox resource notes, the appropriate response is to stop the agent and attempt to identify its nature and components.

This is a shared conversation. Sign in to Orris to start your own chat.